Search clinical trials for: Blopress (Candesartan)

Total 194 results

Kyoto Prefectural University of Medicine

Terminated

Effects of Telmisartan on Ischemic Cardiovascular Events in High-risk Hypertensive Patients (KCPS)

Myocardial Ischemia | Hypertension | Angina Pectoris | Acute Coronary Syndrome | Acute Myocardial Infarction

Japan
Takeda

Terminated

Efficacy of Candesartan on Brain Natriuretic Peptide Levels in Subjects With Chronic Heart Failure (CANDHEART)

Heart Failure
Takeda

Completed

Blopress Tablets Specified Drug-use Survey "Hypertension: Survey on Patients With Metabolic Syndrome"

Hypertension
Takeda

Completed

Efficacy and Safety of Candesartan Cilexetil Plus Hydrochlorothiazide in Subjects With Severe Hypertension

Hypertension

Ukraine, Germany
Takeda

Completed

Candesartan Cilexetil Special Drug Use Surveillance 「Challenge - Quality Control」

Hypertension

Japan
Takeda

Completed

Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension

Essential Hypertension
Augusta University
National Heart, Lung, and Blood Institute (NHLBI)

Active, not recruiting

Adiposity and Endothelin Receptor Function (END-RF)

Hypertension

United States
Takeda

Completed

Efficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and Hypertensive Patients.

Heart Failure

Germany
Takeda

Completed

Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese Patients With Hypertension.

Hypertension | Obesity

Germany
Kumamoto University
Japan Heart Foundation; The 4C trial bureau

Completed

Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial

Coronary Artery Disease | Hypertension

Japan
Boehringer Ingelheim

Completed

Study to Assess Potential Different Properties of Telmisartan Compared to Candesartan in Healthy Volunteers

Healthy
Louise Faerch

Completed

Cognitive Function and Electrocardiogram (ECG) During Hypoglycemia and Blockade of the Renin-angiotensin System

Hypoglycemia | Type 1 Diabetes

Denmark
Göteborg University
Sahlgrenska University Hospital, Sweden

Completed

Expression and Function of the Renin-Angiotensin System in the Esophagus

Barrett's Esophagus

Sweden
GlaxoSmithKline

Completed

Bioavailability Study of Candesartan Cilexetil 16mg Tablet Under Fasting Conditions

Hypertension

India
AstraZeneca

Completed

ARIA (Atacand Renoprotection In NephropAthy Pt.) (PCR)

Non-diabetic Nephropathy With Hypertension

Korea, Republic of
GlaxoSmithKline

Completed

Bioavailability Study of Candesartan Cilexetil 8mg Tablet Under Fasting Conditions

Hypertension

India
GlaxoSmithKline

Completed

Relative Bioavailability Study of Candesartan Cilexetil Under Fasting Conditions

Cardiovascular Disease

India
St. Olavs Hospital
Ullevaal University Hospital; University Hospital of North Norway; Norwegian... and other collaborators

Active, not recruiting

Candesartan for Migraine Prevention: (CandMig-3)

Migraine

Norway, Estonia
AstraZeneca
Takeda

Completed

Diabetic Retinopathy Candesartan Trials (DIRECT)

Type 1 Diabetes

Denmark, Australia
Huazhong University of Science and Technology

Unknown

Study of Optimal Treatment Plan in Hypertensives With Anti-AT1-Receptor Autoantibody

Hypertension

China
AstraZeneca

Completed

High Doses of Candesartan Cilexetil on the Reduction of Proteinuria

Proteinuria

Canada
Herlev Hospital

Unknown

Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease

Cardiovascular Diseases | Kidney Failure, Chronic

Denmark
AstraZeneca

Completed

Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age

Hypertension

United States, France, Italy, United Kingdom, Germany, Poland, Ukraine, Belgium, Puerto Rico, Denmark
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Terminated

Study to Demonstrate the Non-inferiority of Olmesartan Medoxomil Versus Candesartan Cilexetil in Reducing Blood B-type (or Brain) Natriuretic Peptide Levels at Week 24 (OLMEBNP)

Chronic Heart Failure | High Blood B-type (or Brain) Natriuretic Peptide (BNP) Level

Germany, France, Netherlands
Ullevaal University Hospital
Takeda; AstraZeneca; Southern-Eastern Norway Health Authorities RHF

Completed

Scandinavian Candesartan Acute Stroke Trial (SCAST)

Stroke

Norway
Mayo Clinic

Completed

Angiotensin-II Blockade in Mitral Regurgitation

Mitral Regurgitation

United States
AstraZeneca

Completed

Study to Characterize the Long-term Clinical Experience of Atacand in Hypertensive Children Ages 1 to<11 Years (Hypertension in Pediatrics) (HIP)

Hypertension

France, Germany, Poland, Ukraine, Belgium, Italy
GlaxoSmithKline

Completed

A Relative Bioavailability Study of a Fixed Dose Combination (FDC) Tablets of GSK587323

Hypertension

India
Norwegian University of Science and Technology
AstraZeneca

Completed

Prophylactic Treatment of Episodic Cluster Headache

Cluster Headache

Norway
EMS

Withdrawn

Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control

Essential Arterial Hypertension
AstraZeneca

Completed

Atacand (Candesartan) Real Life Study (Real Life)

Hypertension

Sweden
University of Sydney
The George Institute for Global Health, India

Terminated

Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19 (CLARITY 2)

COVID-19 | SARS-CoV2 Infection

India
Bayer

Withdrawn

Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination in Subjects With Essential Hypertension Inadequately Controlled on Candesartan Cilexetil

Hypertension

Italy
Kyorin University
Ministry of Health, Labour and Welfare, Japan

Unknown

CCB Safety Study in Treatment of Hypertension of ADPKD

Kidney, Polycystic, Autosomal Dominant

Japan
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of MK-5478 in Participants With Hypertension (5478-001)

Hypertension
AstraZeneca
Takeda

Completed

DIabetic Retinopathy Candesartan Trials (DIRECT)

Type 2 Diabetes
Pharmtechnology LLC
Altasciences Company, Inc.

Completed

The Bioequivalence Study of Two Different Formulations of Candesartan Cilexetil After a Single Oral Dose Administration Under Fasting Conditions

Bioequivalence

Canada
AstraZeneca

Completed

Bioequivalence Study in Healthy Subjects

Hypertension

United Kingdom
Chong Kun Dang Pharmaceutical

Unknown

A Dose Selection Trial of CKD-330 in Patients With Essential Hypertension

Essential Hypertension

Korea, Republic of
Takeda

Completed

A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and Microalbuminuria

Type 2 Diabetes Mellitus and Microalbuminuria

Japan
Charles University, Czech Republic
AstraZeneca

Unknown

CHANCE - Candesartan in Hypertrophic Cardiomyopathy

Hypertrophic Cardiomyopathy

Czech Republic
Sherief Abd-Elsalam

Recruiting

Effect of Some Drugs on Liver Fibrosis

Liver Fibroses

Egypt
Rambam Health Care Campus

Unknown

Non-Insulin Dependent Diabetes Mellitus (NIDDM) and Angiotensin Converting Enzyme 2 (ACE2): Diabetic Patients Treated With Antihypertensive Drugs

NIDDM

Israel
HK inno.N Corporation

Completed

A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy

Essential Hypertension

Korea, Republic of
AstraZeneca
Takeda

Completed

DIabetic Retinopathy Candesartan Trials. (DIRECT)

Type 1 Diabetes
Slovak Academy of Sciences

Unknown

Changes After Angiotensin Converting Enzyme (ACE) Inhibitor Replacement by Angiotensin II Receptor Type I (AT1) Blocker (ADIRAS)

Hypertension

Slovakia
AstraZeneca
Takeda

Completed

Observational Usage and Efficacy Study of Candesartan in Heart Failure Treatment in France (SISTOLA)

Heart Failure | Cohort Study

France
Mitsubishi Tanabe Pharma Corporation

Completed

Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy Subjects

Chronic Kidney Disease | Hyperphosphatemia

United Kingdom
AstraZeneca

Completed

Efficacy Observational Study of Candesartan Cilexetil on Hypertensive Patients

Primary Hypertension

Romania
Bayer

Completed

Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension (DISTINCT)

Hypertension, Essential

Spain, Argentina, United States, Canada, Korea, Republic of, Italy, Russian Federation, South Africa, Ukraine, Belgium, Brazil, Lithuania, United Kingdom

3

Subscribe